AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug

AstraZeneca Pharmaceuticals LP and other companies settled a dispute with MSN Laboratories Pvt Ltd. alleging infringement of patents for Calquence tablets, a blood-cancer treatment, according to a federal court filing.

MSN is enjoined from infringing certain patents related to the case, according to the consent judgment issued Dec. 22 by the US District Court for the District of Delaware.

• The pharmaceutical companies’ complaint said MSN’s version of the tablets, which have a 100-milligram base equivalent of Calquence’s active ingredient, acalabrutinib maleate, infringed two of its patents
• The lawsuit came several months after MSN settled a case over the blockbuster drug’s ...